Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS6
PHASE 3 / 2-36
RECRUITING6
READOUTS ≤12 MONTHS3
| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| KarXT NCT05511363 |
P3 | Recruiting | Psychosis Associated With Alzheimer's Disease | 410 | 2026-10-05 (+19 mo) |
| KarXT NCT06585787 |
P3 | Recruiting | Alzheimer Disease | 406 | 2026-11-24 |
| KarXT NCT06126224 |
P3 | Recruiting | Psychosis Associated With Alzheimer's Disease | 500 | 2026-12-09 (+17 mo) |
| KarXT NCT05980949 |
P3 | Recruiting | Psychosis Associated With Alzheimer's Disease | 1000 | 2027-09-07 (+17 mo) |
| Xanomeline/Trospium Chloride NCT07686263 |
P3 | Recruiting | Schizophrenia | 472 | 2029-03-03 |
| KarXT NCT07424404 |
P3 | Recruiting | Schizophrenia; Autism-Related Irritability | 400 | 2030-03-08 |